Skip to main content
SpringerLink
Log in

Surgical Management of Hereditary Breast and Ovarian Cancer

  • Chapter
  • First Online:
Principles of Clinical Cancer Genetics

  • 1300 Accesses

Abstract

Hereditary breast cancer may result from germline mutations in one of several genes. Different genes confer different levels of risk for the development of breast cancer, and may also confer a significantly increased risk of cancer in other organ sites. For example, mutations and the BRCA1 and BRCA2 genes, the most common cause of hereditary breast cancer, also markedly increase the risk of ovarian cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Ford D, Easton DF, Stratton M et al (1998) Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. Am J Hum Genet 62:676–689

    Article  PubMed  CAS  Google Scholar 

  2. Antoniou A, Pharoah PD, Narod S et al (2003) Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 72:1117–1130

    Article  PubMed  CAS  Google Scholar 

  3. King MC, Marks JH, Mandell JB (2003) Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science 302:643–646

    Article  PubMed  CAS  Google Scholar 

  4. Chen S, Iverson ES, Friebel T et al (2006) Characterization of BRCA1 and BRCA2 mutations in a large United States sample. J Clin Oncol 24:863–871

    Article  PubMed  CAS  Google Scholar 

  5. Hartmann LC, Sellers TA, Schaid DJ et al (2001) Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer. J Natl Canc Inst 93:1633–1637

    Article  CAS  Google Scholar 

  6. Rebbeck TR, Friebel T, Lynch HT et al (2004) Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J Clin Oncol 22:1055–1062

    Article  PubMed  Google Scholar 

  7. Meijers-Heijboer H, van Geel B, van Putten WL et al (2001) Breast cancer after prophylactic mastectomy in women with a BRCA 1 or 2 mutation. N Engl J Med 354:159–164

    Article  Google Scholar 

  8. Rebbeck TR et al (2002) The Prevention and Observation of Surgical End Points Study Group: prophylactic oophorectomy in carriers of BRCA 1 or BRCA2 mutations. N Eng J Med 346:1616–1622

    Article  Google Scholar 

  9. Ray J, Loescher L, Brewer M (2005) Risk-reduction surgery decisions in high-risk women seen for genetic counseling. J Genet Couns 14:473–484

    Article  PubMed  Google Scholar 

  10. Uyei A, Peterson SK, Erlichman J et al (2006) Association between clinical characteristics and risk-reduction interventions in women who underwent BRCA1 and BRCA2 testing. Cancer 107:2745–2751

    Article  PubMed  CAS  Google Scholar 

  11. Beattie MS, Crawford B, Lin F et al (2009) Uptake, time course and predictors of risk-reducing surgeries in BRCA carriers. Genet Test Mol Biosmarkers 13:51–56

    Article  Google Scholar 

  12. Litton JK, Westin SN, Ready K et al (2009) Perception of screening and risk reduction surgeries in patients tested for a BRCA deleterious mutation. Cancer 115:1598–1604

    Article  PubMed  Google Scholar 

  13. Frost MH, Schaid DJ, Sellers TA et al (2000) Long-term satisfaction and psychological and social function following bilateral prophylactic mastectomy. JAMA 284:319–324

    Article  PubMed  CAS  Google Scholar 

  14. Geiger AM, Nekhlyudov L, Herrinton LJ et al (2006) Quality of life after bilateral prophylactic mastectomy. Ann Surg Oncol 14:686–694

    Article  PubMed  Google Scholar 

  15. Van Oostrom I, Meijers-Heijboer H, Lodder LN et al (2003) Long-term psychologic impact of carrying a BRCA1/2 mutation and prophylactic surgery: a 5-year follow-up study. J Clin Oncol 21:3867–3874

    Article  PubMed  Google Scholar 

  16. Li FP, Fraumeni JF Jr, Mulvihill JJ et al (1988) A cancer family syndrome in twenty-four kindreds. Cancer Res 48:5358–5362

    PubMed  CAS  Google Scholar 

  17. Sidransky D, Tokino T, Helzlsouer K et al (1992) Inherited p53 gene mutations in breast cancer. Cancer Res 52:2984–2986

    PubMed  CAS  Google Scholar 

  18. Birch JM, Alston RD, McNally RJ et al (2001) Relative frequency and morphology of cancers in carriers of germline TP53 mutations. Oncogene 20:4621–4628

    Article  PubMed  CAS  Google Scholar 

  19. Chompret A, Brugieres L, Ronsin M et al (2000) P53 germline mutations in childhood cancers and cancer risk for carrier individuals. Br J Cancer 82:1932–1937

    Article  PubMed  CAS  Google Scholar 

  20. Le Bihan C, Bonaiti-Pellie C (1994) A method for estimating cancer risk in p53 mutation carriers. Cancer Detect Prev 18:171–178

    PubMed  Google Scholar 

  21. Eng C (2003) PTEN: one gene, many syndromes. Hum Mutat 22:183–198

    Article  PubMed  CAS  Google Scholar 

  22. Starink TM, van der Veen JP, Arwert F et al (1986) The Cowden syndrome: a clinical and genetic study in 21 patients. Clin Genet 29:222–233

    Article  PubMed  CAS  Google Scholar 

  23. Pharoah P, Guilford P, Caldas C et al (2001) Incidence of gastric cancer and breast cancer in CDH1 (E-cadherin) mutation carriers from hereditary diffuse gastric cancer families. Gastroenterology 121:1348–1353

    Article  PubMed  CAS  Google Scholar 

  24. Norton JA, Ham CM, Van Dam J et al (2007) CDH1 truncating mutations in the E-cadherin gene an indication for total gastrectomy to treat hereditary diffuse gastric cancer. Ann Surg 245:873–879

    Article  PubMed  Google Scholar 

  25. Beer GM, Varga Z, Budi S, Seifert B, Meyer VE (2002) Incidence of the superficial fascia and its relevance in skin-sparing mastectomy. Cancer 94:1619–1625

    Article  PubMed  Google Scholar 

  26. Ho CM, Mak CK, Lau Y, Cheung WY, Chan MC, Hung WK (2003) Skin involvement in invasive breast carcinoma: safety of skin-sparing mastectomy. Ann Surg Oncol 10:102–107

    Article  PubMed  Google Scholar 

  27. Carlson GW, Styblo TM, Lyles RH, Jones G, Murray DR, Staley CA et al (2003) The use of skin sparing mastectomy in the treatment of breast cancer: The Emory experience. Surg Oncol 12:265–269

    Article  PubMed  Google Scholar 

  28. Gerber B, Krause A, Reimer T, Muller H, Kuchenmeister I, Makovitzky J et al (2003) Skin-sparing mastectomy with conservation of the nipple-areola complex and autologous reconstruction is an oncologically safe procedure. Ann Surg 238:120–127

    PubMed  Google Scholar 

  29. Greenway RM, Schlossberg L, Dooley WC (2005) Fifteen-year series of skin-sparing mastectomy for stage 0 to 2 breast cancer. Am J Surg 190:918–922

    Article  PubMed  Google Scholar 

  30. Kroll SS, Khoo A, Singletary SE, Ames FC, Wang BG, Reece GP et al (1999) Local recurrence risk after skin-sparing and conventional mastectomy: a 6-year follow-up. Plast Reconstr Surg 104:421–425

    Article  PubMed  CAS  Google Scholar 

  31. Spiegel AJ, Butler CE (2003) Recurrence following treatment of ductal carcinoma in situ with skin-sparing mastectomy and immediate breast reconstruction. Plast Reconstr Surg 111:706–711

    Article  PubMed  Google Scholar 

  32. Drucker-Zertuche M, Robles-Vidal C (2007) A 7-year experience with immediate breast reconstruction after skin sparing mastectomy for cancer. Eur J Surg Oncol 33:140–146

    Article  PubMed  CAS  Google Scholar 

  33. Carlson GW, Page A, Johnson E et al (2007) Local recurrence of ductal carcinoma in situ after skin-sparing mastectomy. J Am Coll Surg 204:1074–1080

    Article  PubMed  Google Scholar 

  34. Salhab M, Al Sarakbi W, Joseph A et al (2006) Skin-sparing mastectomy and immediate breast reconstruction: patient satisfaction and clinical outcomes. In J Clin Oncol 11:51–54

    Article  Google Scholar 

  35. Chung A, Sacchini V (2008) Nipple-sparing mastectomy: where are we now? Surg Oncol 17:261–266

    Article  PubMed  Google Scholar 

  36. Rusby JE, Kirstein LJ, Brachtel EF, Taghian AG, Michaelson JS, Koerner FC, Smith BL et al (2008) Nipple sparing mastectomy: lessons from ex-vivo procedures. Breast J 14:464–470

    Article  PubMed  Google Scholar 

  37. Crowe JP Jr, Kim JA, Yetman R, Banbury J, Patrick RJ, Baynes D (2004) Nipple-sparing mastectomy: technique and results of 54 procedures. Arch Surg 139:148–150

    Article  PubMed  Google Scholar 

  38. Crowe JP, Patrick RJ, Yetman RJ, Djohan R (2008) Nipple-sparing mastectomy update: one hundred forty-nine procedures and clinical outcomes. Arch Surg 143:1106–1110

    Article  PubMed  Google Scholar 

  39. Stolier AJ, Sullivan SK, Dellacroce FJ (2008) Technical considerations in nipple-sparing mastectomy: 82 consecutive cases without necrosis. Ann Surg Oncol 15:1341–1347

    Article  PubMed  Google Scholar 

  40. Caruso F, Ferrara M, Castiglione G, Trombetta G, De Meo L, Catanuto G et al (2006) Nipple sparing subcutaneous mastectomy: sixty-six months follow-up. Eur J Surg Oncol 32:937–940

    Article  PubMed  CAS  Google Scholar 

  41. Petit JY, Veronesi U, Orecchia R, Luini A, Rey P, Intra M et al (2006) Nipple-sparing mastectomy in association with intra operative radiotherapy (ELIOT): a new type of mastectomy for breast cancer treatment. Breast Cancer Res Treat 96:47–51

    Article  PubMed  Google Scholar 

  42. Sacchini V, Pinotti JA, Barros AS et al (2006) Nipple-sparing mastectomy for breast cancer and risk reduction: oncologic or technical problem? J Am Coll Surg 203:704–714

    Article  PubMed  Google Scholar 

  43. Brachtel EF, Rusby JE, Michaelson JS, Smith BL, Koerner FC (2009) Occult nipple involvement in breast cancer: Clinico­pathologic findings in 316 consecutive mastectomy specimens. J Clin Oncol 27:4948–4954

    Article  PubMed  Google Scholar 

  44. Wijayanayagam A, Kumar AS, Foster RD, Esserman LJ (2008) Optimizing the total skin-sparing mastectomy. Arch Surg 143:38–45

    Article  PubMed  Google Scholar 

  45. Bresser PJ, Seynaeve C, Van Gool AR et al (2006) Satisfaction with prophylactic surgery and breast reconstruction in genetically predisposed women. Plast Reconstr Surg 118:1496–1497

    Article  Google Scholar 

  46. Black DS, Specht MC, Lee JM et al (2007) Detecting occult malignancy in prophylactic mastectomy: preoperative MRI vs. sentinel lymph node biopsy. Ann Surg Oncol 14:2477–2484

    Article  PubMed  Google Scholar 

  47. McLaughlin SA, Stempal M, Morris EA, Liberman L, King TA (2007) Can magnetic resonance imaging be used to select patients for sentinel lymph node biopsy in prophylactic mastectomy? Cancer 112:1214–1221

    Article  Google Scholar 

  48. Pierce LJ, Strawderman M, Narod SA et al (2000) Effect of radiotherapy after breast-conserving treatment in women with breast cancer and germline BRCA1/2 mutations. J Clin Oncol 19:3360–3369

    Google Scholar 

  49. Pierce LJ, Levin AM, Rebbeck TR et al (2006) Ten-year multi-institutional results of breast conserving surgery and radiotherapy in BRCA ½-associated Stage I or II breast cancer. J Clin Oncol 24:2437–2443

    Article  PubMed  Google Scholar 

  50. De Bock GH, Tollenaar RA, Papelard H et al (2001) Clinical and pathological features of BRCA 1 associated carcinomas in a hospital-based sample of Dutch breast cancer patients. Br J Cancer 85:347–350

    Article  Google Scholar 

  51. Lakhani SR, van De Vijver MJ, Jacquemier J et al (2002) The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER2, and p53 in patients with mutations in BRCA 1 and BRCA2. J Clin Oncol 20:2310–2318

    Article  PubMed  CAS  Google Scholar 

  52. Veronesi A, de Giacomi C, Magri MD et al (2005) Familial breast cancer: characteristics and outcome of BRCA1-2 positive and negative cases. BMC Cancer 5:70–75

    Article  PubMed  Google Scholar 

  53. Robson M, Svahn T, McCormick B et al (2005) Appropriateness of breast-conserving treatment of breast carcinoma in women with germline mutations in BRCA1 or BRCA2: a clinic-based series. Cancer 103:44–51

    Article  PubMed  Google Scholar 

  54. Metcalfe K, Lynch HT, Ghadirian P et al (2004) Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers. J Clin Oncol 22:2328–2335

    Article  PubMed  CAS  Google Scholar 

  55. Disa JJ, McCarthy CM, Mehrara BJ, Pusic AL, Cordeiro PG (2008) Immediate latissimus dorsi/prosthetic breast reconstruction following salvage mastectomy after failed lumpectomy/irradiation. Plastic Reconstr Surg 121:159–164

    Article  Google Scholar 

  56. ACS (2009) Cancer facts and figures 2009, American Cancer Society, Atlanta, GA

    Google Scholar 

  57. Garber JE, Offit K (2005) Hereditary cancer predisposition syndromes. J Clin Oncol 23:276–292

    Article  PubMed  Google Scholar 

  58. Struewing JP, Hartge P, Wacholder S et al (1997) The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med 336:1401–1408

    Article  PubMed  CAS  Google Scholar 

  59. Frank TS (2001) Hereditary cancer syndromes. Arch Pathol Lab Med 125:85–90

    PubMed  CAS  Google Scholar 

  60. Chen S, Parmigiani G (2007) Meta-analysis of BRCA1 and BRCA2 penetrance. J Clin Oncol 25:1329–1333

    Article  PubMed  Google Scholar 

  61. Ford D, Easton DF, Bishop DT et al (1994) Risk of cancer in BRCA1 mutation carriers. Lancet 343:692–695

    Article  PubMed  CAS  Google Scholar 

  62. Levine DA, Argenta PA, Yee CJ et al (2005) Fallopian tube and primary peritoneal carcinomas associated with BRCA mutations. J Clin Oncol 21:4222–4227

    Article  Google Scholar 

  63. Struewing JP, Watson P, Eaton DF et al (1995) Prophylactic oophorectomy in inherited breast/ovarian cancer families. J Natl Cancer Inst Monogr 17:33–35

    PubMed  Google Scholar 

  64. Weber BL, Punzalan C, Eisen A et al (2000) Ovarian cancer risk reduction after bilateral prophylactic oophorectomy in BRCA1 and BRCA2 mitation carriers. Am Soc Hum Genet 67(Suppl 2):59 (abstract 251)

    Google Scholar 

  65. Piver MS, Jishi MF, Tsukada Y, Nava G (1993) Primary peritoneal carcinoma after prophylactic oophorectomy in women with a family history of ovarian cancer. A report of the Gilda Radner Familial Ovarian Cancer Registry. Cancer 71:2751–2755

    Article  PubMed  CAS  Google Scholar 

  66. Kauff ND, Satagopan JM, Robson ME et al (2002) Risk-reducing salpingo-oophorectomy in women with a BRCA 1 or BRCA 2 mutation. N Engl J Med 346:1609–1615

    Article  PubMed  Google Scholar 

  67. Schrag D, Kuntz KM, Garber JE, Weeks JC (1997) Decision analysis-effects of prophylactic mastectomy and oophorectomy on life expectancy among women with BRCA1 or BRCA2 mutations. N Engl J Med 336:1465–1471

    Article  PubMed  CAS  Google Scholar 

  68. Kauff ND, Domchek SM, Friebel TM et al (2008) Risk-reducing salpingo-oophrectomy for the prevention of BRCA 1 and BRCA 2 associated breast and gynecologic cancer: A multicenter, prospective study. J Clin Oncol 26:1331–1337

    Article  PubMed  Google Scholar 

  69. Rosen B, Kwon K, Fung K, Fung M et al (2004) Systematic review of management options of women with a hereditary predisposition to ovarian cancer. Gynecol Oncol 93:280–286

    Article  PubMed  Google Scholar 

  70. Finch A, Beiner M, Lubinski J et al (2006) Salpingo-oophrectomy in women with a BRCA 1 or BRCA2 mutation. JAMA 296:185–192

    Article  PubMed  CAS  Google Scholar 

  71. Domchek SM, Friebel TM, Neuhausen SL et al (2006) Mortality after bilateral salpingo-oophorectomy for the prevention of BRCA1 and BRCA2 mutation carriers: a prospective cohort study. Lancet Oncol 7:223–229

    Article  PubMed  CAS  Google Scholar 

  72. Brose MS, Rebbeck TR, Calzone KA et al (2002) Cancer risk estimates for BRCA1 mutation carriers indentified in a risk evaluation program. J Natl Cancer Inst 94:1365–1372

    Article  PubMed  CAS  Google Scholar 

  73. Finch A, Shaw P, Rosen B et al (2006) Clinical and pathologic findings of prophylactic salpingo-oophorectomies in 159 BRCA1 and BRCA2 mutation carriers. Gynecol Oncol 100:58–64

    Article  PubMed  CAS  Google Scholar 

  74. Zhou J, Iwasa Y, Konishi I et al (1995) Papillary serous carcinoma of the peritoneum in women. A clinicopathologic and immunohistochemical study. Cancer 76:429–436

    Article  PubMed  CAS  Google Scholar 

  75. Eisen A, Rebbeck TR, Wood WC, Webber BL (2000) Prophylactic surgery in women with a hereditary predisposition to breast and ovarian cancer. J Clin Oncol 18:1980–1995

    PubMed  CAS  Google Scholar 

  76. Dowdy SC, Stefanek M, Hartmann LC (2004) Surgical risk reduction: prophylactic salpingo-oophorectomy and prophylactic mastectomy. Am J Obstet Gynecol 191:1113–1123

    Article  PubMed  Google Scholar 

  77. Powell CB, Kenley E, Chen LM et al (2005) Risk-reducing salpingo-oophorectomy in BRCA mutation carriers: role of serial sectioning in the detection of occult malignancy. J Clin Oncol 23:127–132

    Article  PubMed  Google Scholar 

  78. Powell CB (2006) Occult ovarian cancer at the time of risk-reducing salpingo-oophorectomy. Gynecol Oncol 100:1

    Article  PubMed  Google Scholar 

  79. Guillem JG, Wood WC, Moley JF et al (2006) ASCO/SSO review of current role of risk-reducing surgery in common hereditary cancer syndromes. J Clin Oncol 24:4642–4660

    Article  PubMed  Google Scholar 

  80. Lu KH, Garber JE, Cramer DW et al (2000) Occult ovarian tumors in women with BRCA1 or BRCA2 mutations undergoing prophylactic oophorectomy. J Clin Oncol 18:2728–2732

    PubMed  CAS  Google Scholar 

  81. Kauff ND, Barakat RR (2004) Surgical risk-reduction in carriers of BRCA mutations: where do we go from here? Gynecol Oncol 93:277–279

    Article  PubMed  Google Scholar 

  82. (2005) Society of Gynecologic Oncologists Clinical Practice Committee Statement on Prophylactic Salpingo-oophorectomy. Gynecol Oncol 98:179–181

    Google Scholar 

  83. Watson P, Lynch HT (1993) Extracolonic cancer in hereditary nonpolyposis colorectal cancer. Cancer 71:677–685

    Article  PubMed  CAS  Google Scholar 

  84. Lavie O, Hornreich G, Ben Arie A et al (2000) BRCA1 germline mutations in women with uterine serous papillary carcinoma. Obstet Gynecol 96:28–32

    Article  PubMed  CAS  Google Scholar 

  85. Hornreich G, Beller U, Lavie O et al (1999) Is uterine serous papillary carcinoma a BRACA1-related disease? Case report and review of the literature. Gynecol Oncol 75:300–304

    Article  PubMed  CAS  Google Scholar 

  86. Lavie O, Hornreich G, Ben Arie A et al (2004) BRCA germline mutations in Jewish women with uterine serous papillary carcinoma. Gynecol Oncol 92:521–524

    Article  PubMed  CAS  Google Scholar 

  87. Goshen R, Chu W, Elit L et al (2000) Is uterine papillary serous adenocarcinoma a manifestation of the hereditary breast-ovarian cancer syndrome? Gynecol Oncol 79:477–481

    Article  PubMed  CAS  Google Scholar 

  88. Rubinstein WS (2005) Surgical management of BRCA1 and BRCA2 carriers: bitter choices slightly sweetened. J Clin Oncol 23:7772–7774

    Article  PubMed  Google Scholar 

  89. Villella JA, Parmar M, Donohue K et al (2006) Role of prophylactic hysterectomy in patients at high risk for hereditary cancers. Gynecol Oncol 102:475–479

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Harvard Medical School, Massachusetts General Hospital Cancer Center, Boston, MA, USA

    Barbara L. Smith

Authors
  1. Michelle C. Specht
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Marcela G. del Carmen
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Barbara L. Smith
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Cancer Center and Gastrointestinal Unit, Harvard Medical School, Massachusetts General Hospital, Boston, 02114, USA

    Daniel C. Chung

  2. Cancer Center, Harvard Medical School and, Massachusetts General Hospital, Boston, 02114, USA

    Daniel A. Haber

Rights and permissions

Reprints and permissions

Copyright information

© 2010 Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Specht, M.C., del Carmen, M.G., Smith, B.L. (2010). Surgical Management of Hereditary Breast and Ovarian Cancer. In: Chung, D., Haber, D. (eds) Principles of Clinical Cancer Genetics. Springer, Boston, MA. https://doi.org/10.1007/978-0-387-93846-2_4

Download citation

  • DOI: https://doi.org/10.1007/978-0-387-93846-2_4

  • Published:

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-0-387-93844-8

  • Online ISBN: 978-0-387-93846-2

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation